WO2002040692A3 - Gefässendothel-spezifischer promotor des humanen vascular endothelial cadherin-2 (hve-cad-2) gens und seine therapeutischen verwendungen - Google Patents

Gefässendothel-spezifischer promotor des humanen vascular endothelial cadherin-2 (hve-cad-2) gens und seine therapeutischen verwendungen Download PDF

Info

Publication number
WO2002040692A3
WO2002040692A3 PCT/EP2001/013321 EP0113321W WO0240692A3 WO 2002040692 A3 WO2002040692 A3 WO 2002040692A3 EP 0113321 W EP0113321 W EP 0113321W WO 0240692 A3 WO0240692 A3 WO 0240692A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
gene
cad
hve
vascular endothelial
Prior art date
Application number
PCT/EP2001/013321
Other languages
English (en)
French (fr)
Other versions
WO2002040692A2 (de
Inventor
Robert Zweigerdt
Manfred Ruediger
Thomas G Moll
Original Assignee
Cardion Ag
Robert Zweigerdt
Manfred Ruediger
Thomas G Moll
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardion Ag, Robert Zweigerdt, Manfred Ruediger, Thomas G Moll filed Critical Cardion Ag
Priority to AU2002220711A priority Critical patent/AU2002220711A1/en
Priority to IL15590701A priority patent/IL155907A0/xx
Priority to EP01996615A priority patent/EP1392836A2/de
Priority to CA002429317A priority patent/CA2429317A1/en
Publication of WO2002040692A2 publication Critical patent/WO2002040692A2/de
Publication of WO2002040692A3 publication Critical patent/WO2002040692A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Die Erfindung betrifft ein Nukleinsäure-Fragment, enthaltend die regulatorische Sequenz des VE-Cad-2-Gens, komplett oder eine funktionell aktive Variante davon; ein Nukleinsäure-Konstrukt enthaltend das Nukleinsäure-Fragment und eine funktionale Nukleinsäure-Sequenz oder ein heterologes Gen; einen Vektor oder ein Vektorsystem; eine Zelle oder Zellinie; ein transgenes nicht-menschliches Tier; ein Arzneimittel; ein Diagnostikum; ein Array; ein Verfahren zur Identifizierung von pharmakologisch aktiven Substanzen; ein Verfahren zur Identifizierung von funktionell aktiven Varianten; ein Verfahren zur Isolierung von Endothelzellen aus Stammzellen; ein Verfahren zur Behandlung; ein Verfahren zur Verabreichung eines Arzneimittels; die Verwendung des Nukleinsäure-Fragments, des Nukleinsäure-Konstrukts, der transformierte Zelle oder Zellinie des Tests und des Arrays.
PCT/EP2001/013321 2000-11-16 2001-11-16 Gefässendothel-spezifischer promotor des humanen vascular endothelial cadherin-2 (hve-cad-2) gens und seine therapeutischen verwendungen WO2002040692A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002220711A AU2002220711A1 (en) 2000-11-16 2001-11-16 Specific promoter of the human vascular endothelial cadherin-2 (hve-cad-2) gene and the therapeutic uses thereof
IL15590701A IL155907A0 (en) 2000-11-16 2001-11-16 Specific promotor of the human vascular endothelial cadherin-2-(hve-cad-2) gene and the therapeutic uses thereof
EP01996615A EP1392836A2 (de) 2000-11-16 2001-11-16 Gefässendothel-spezifischer promotor des humanen vascular endothelial cadherin-2 (hve-cad-2) gens und seine therapeutischen verwendungen
CA002429317A CA2429317A1 (en) 2000-11-16 2001-11-16 Specific promoter of the human vascular endothelial cadherin-2 (hve-cad-2) gene and the therapeutic uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24939000P 2000-11-16 2000-11-16
US60/249,390 2000-11-16

Publications (2)

Publication Number Publication Date
WO2002040692A2 WO2002040692A2 (de) 2002-05-23
WO2002040692A3 true WO2002040692A3 (de) 2002-11-14

Family

ID=22943270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/013321 WO2002040692A2 (de) 2000-11-16 2001-11-16 Gefässendothel-spezifischer promotor des humanen vascular endothelial cadherin-2 (hve-cad-2) gens und seine therapeutischen verwendungen

Country Status (5)

Country Link
EP (1) EP1392836A2 (de)
AU (1) AU2002220711A1 (de)
CA (1) CA2429317A1 (de)
IL (1) IL155907A0 (de)
WO (1) WO2002040692A2 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2756570A1 (fr) * 1996-12-03 1998-06-05 Commissariat Energie Atomique Promoteur de la ve-cadherine et ses utilisations
WO2001055214A2 (en) * 2000-01-25 2001-08-02 Novartis Ag Asthma-associated gene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2756570A1 (fr) * 1996-12-03 1998-06-05 Commissariat Energie Atomique Promoteur de la ve-cadherine et ses utilisations
WO2001055214A2 (en) * 2000-01-25 2001-08-02 Novartis Ag Asthma-associated gene

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EM_HUM [online] EMBL; 2 October 1998 (1998-10-02), KIMMERLY ET AL.: "Homo sapiens chromosome 5p, BAC clone 50g21 (LBNL H154), complete sequence", XP002201114, retrieved from EBI accession no. AC005740 *
DATABASE EM_HUM [online] EMBL; 7 June 2000 (2000-06-07), LUDWIG ET AL.: "Homo sapiens vascular endothelial cadherin 2 mRNA, complet cds.", XP002201115, retrieved from EBI accession no. AF240635 *
LUDWIG ET AL.: "cDna cloning, chromosomal mapping, and expression analysis of human VE-cadherin-2", MAMMALIAN GENOME, vol. 11, no. 11, 2000, pages 1030 - 1033, XP002201113, Retrieved from the Internet <URL:EBI> *
SCHLAEGER T M ET AL: "VASCULAR ENDOTHELIAL CELL LINEAGE-SPECIFIC PROMOTER IN TRANSGENIC MICE", DEVELOPMENT, COMPANY OF BIOLOGISTS, CAMBRIDGE,, GB, vol. 121, no. 4, 1995, pages 1089 - 1098, XP000604125, ISSN: 0950-1991 *

Also Published As

Publication number Publication date
IL155907A0 (en) 2003-12-23
WO2002040692A2 (de) 2002-05-23
AU2002220711A1 (en) 2002-05-27
EP1392836A2 (de) 2004-03-03
CA2429317A1 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
Arima et al. Brain micro-inflammation at specific vessels dysregulates organ-homeostasis via the activation of a new neural circuit
WO2004011624A3 (en) Double stranded rna structures and constructs, and methods for generating and using the same
WO2004035765A3 (en) Double-stranded rna structures and constructs, and methods for generating and using the same
NZ524894A (en) Antisense oligonucleotides against VR1
ATE406453T1 (de) Verfahren zür einführung und expression von genen in tierischen zellen
EP1199360A3 (de) Aktive und inactive CC-Chemokinrezeptoren und Nukleinsäuremoleküle, die für diesen Rezeptor kodieren
WO1998051325A3 (en) Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods
US11273137B2 (en) Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene
DK1053313T3 (da) Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser
CN111868240A (zh) 靶向crispr递送平台
WO2012016081A2 (en) Method and therapeutic for the treatment and regulation of memory formation
Schluesener et al. Transient in vivo activation of rat brain macrophages/microglial cells and astrocytes by immunostimulatory multiple CpG oligonucleotides
Shuttleworth et al. Antisense oligodeoxyribonucleotide-directed cleavage of maternal mRNA in Xenopus oocytes and embryos
Pizzo et al. The success of the RNase scaffold in the advance of biosciences and in evolution
US20020102568A1 (en) Nucleic acid sensor molecules
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
Xu et al. Inhibition of DRG-TRPV1 upregulation in myocardial ischemia contributes to exogenous cardioprotection
WO1998054313A3 (en) Dna methyltransferase genomic sequences and antisense oligonucleotides
WO2002022662A3 (en) Insect inhibitory bacillus thuringiensis proteins, fusions, and methods of use therefor
NZ504445A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
WO2002040692A3 (de) Gefässendothel-spezifischer promotor des humanen vascular endothelial cadherin-2 (hve-cad-2) gens und seine therapeutischen verwendungen
KR100958291B1 (ko) Ｔ―타입 칼슘채널을 억제하여 불안 장애를 치료하는 방법
WO2001002020A3 (en) Compositions and methods for targeted enzymatic release of cell regulatory compounds
CN113557036A (zh) 基因编辑以改善关节功能
Skutella et al. Localization of tyrosine hydroxylase mRNA in the axons of the hypothalamo-neurohypophysial system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 155907

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2429317

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001996615

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001996615

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001996615

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP